Therapy News and Research

RSS

APF launches new educational initiative for people with pain, health care professionals

The American Pain Foundation today announced the launch of PainSAFE (Pain Safety & Access For Everyone), a new educational initiative designed for people with pain and health care professionals. The mission of PainSAFE is to provide education surrounding the appropriate and safe use of pain management therapies for people affected by pain and health care professionals, thereby, helping to reduce risk and improve access to quality pain care.

22 Sep 2010

Scientists develop new therapy for treatment of skin, lung cancer

Scientists at the University of Granada have developed a new therapy for the treatment of skin and lung cancer. This therapy involves the use of a suicide coliphage-gene (gene E) that can induce death to cells transfected with it.. Their studies have demostrated that this technique is not only effective in vitro (using tumour cell cultures), but also in vivo through the use of experimental animals in which tumours were induced.

22 Sep 2010

G-CSF compound may activate virus, increases risk of infection: Research

Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute may spur debate about the risks associated with administering a specific compound in some forms of bone-marrow transplantation. The research is published in the current edition of Cell Host and Microbe.

22 Sep 2010

Titan completes enrollment in Probuphine Phase 3 study for opioid addiction

Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.

22 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

Paper calls for revision of STEMI guidelines around oxygen therapy

The European Society of Cardiology welcomes a paper published today in the Journal of the American College of Cardiology highlighting concerns over the use of oxygen therapy during MI in patients with normal oxygen levels. The publication adds to calls for revision of the STEMI guidelines around oxygen therapy and for a prospective, large scale randomised trials, issues that were both first raised in a Cochrane Review published in June.

22 Sep 2010

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.

22 Sep 2010

ImThera Medical releases interim results of clinical study on neurostimulation device for treating OSA

ImThera Medical, Inc. today announced interim results from its OSA European clinical study. For the study, ten patients have been surgically implanted with ImThera's aura6000 hypoglossal nerve neurostimulation device for treating Obstructive Sleep Apnea. The target population for ImThera's neurostimulation device is moderate and severe OSA patients who are non-compliant with or cannot tolerate Continuous Positive Airway Pressure.

22 Sep 2010

George Higginson Professor to receive 2010 Warren Alpert Foundation Prize

Howard Green, a founding father of regenerative medicine and the George Higginson Professor of Cell Biology at Harvard Medical School, will receive the 2010 Warren Alpert Foundation Prize for developing methodologies leading directly to permanent skin restoration therapy which is saving the lives of thousands of burn patients around the world.

22 Sep 2010

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.

22 Sep 2010

Patient follow-up complete in SANUWAVE's dermaPACE Phase III IDE trial for diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced the completion of patient follow-up in the Company's pivotal Phase III, Investigational Device Exemption (IDE) clinical trial with dermaPACE™ for the treatment of diabetic foot ulcers.

22 Sep 2010

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

The first in-human study of a robotically assisted percutaneous coronary intervention system demonstrated that the technique was safe and feasible. The results of the study were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

22 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

A potential immunotherapy, a new gene therapy, an enzyme inhibitor, and a compound originally isolated from a Chinese herb are among the latest approaches scientists are proposing to treat addiction.

22 Sep 2010

Study demonstrates why targeted therapies do not work in majority of people

In order for targeted therapies against cancer to be effective, scientists need to understand upfront what related proteins in a signaling "network" makes a cancer cell resistant to a drug and selectively target them as well, say researchers at Georgetown Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center.

22 Sep 2010

Physical or psychological stress before cancer treatment may sabotage therapy

Patients who experience physical or psychological stress - including rigorous exercise - one or two days before a cancer treatment might be unknowingly sabotaging their therapy, new research suggests.

22 Sep 2010

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Novartis Pharmaceuticals Corporation announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal. Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).

22 Sep 2010

Catheter ablation benefits atrial fibrillation patients younger than 45

Patients under age 45 had fewer major complications than older patients and comparable improvement after a medical procedure to treat irregular heartbeat, or arrhythmia, in a study reported in Circulation: Arrhythmia and Electrophysiology, an American Heart Association journal.

22 Sep 2010

Study: New percutaneous mitral valve clip offers marked clinical benefit

A percutaneous mitral valve clip designed to stop mitral valve regurgitation demonstrated clinical benefit as measured by the degree of mitral regurgitation, according to a study presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

22 Sep 2010

Deep brain stimulation improves OCD symptoms, promotes smoking cessation and weight loss

Electrical stimulation of the brain in a patient with severe obsessive-compulsive disorder (OCD) led to some unanticipated benefits—"effortless" smoking cessation and weight loss, according to a case report in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

22 Sep 2010

Therapy News and Research

APF launches new educational initiative for people with pain, health care professionals

Scientists develop new therapy for treatment of skin, lung cancer

G-CSF compound may activate virus, increases risk of infection: Research

Titan completes enrollment in Probuphine Phase 3 study for opioid addiction

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Paper calls for revision of STEMI guidelines around oxygen therapy

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

ImThera Medical releases interim results of clinical study on neurostimulation device for treating OSA

George Higginson Professor to receive 2010 Warren Alpert Foundation Prize

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Patient follow-up complete in SANUWAVE's dermaPACE Phase III IDE trial for diabetic foot ulcers

First in-human study of robotically assisted percutaneous coronary intervention system presented at 22nd TCT

AACR to host fourth International Conference on Molecular Diagnostics

NIDA's Avant-Garde Awards support novel approaches for treating tobacco and cocaine addiction

Study demonstrates why targeted therapies do not work in majority of people

Physical or psychological stress before cancer treatment may sabotage therapy

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Catheter ablation benefits atrial fibrillation patients younger than 45

Study: New percutaneous mitral valve clip offers marked clinical benefit

Deep brain stimulation improves OCD symptoms, promotes smoking cessation and weight loss

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News